All News
🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of patients with refractory #gout on b/g xanthine oxidase inhibitor. >50% on 60 mg/day reached sUA <3 mg/dL.
💊Potential new oral ULT option.
@RheumNow #EULAR2025 #LB0008 https://t.co/dfY1V5sHSh
Mrinalini Dey DrMiniDey ( View Tweet)
Why do Rheumatologists shift to private practice? Are there gender based differences?
A survey of 100+ European rheumatologists
Female 🚺 rheumatologists:
Leave hospital earlier
At a lower hierarchical level
Reasons for leaving:
nightshifts
unfair promotion decisions
Aurelie Najm AurelieRheumo ( View Tweet)
EULAR PtC for definition of #TR Trt Refractory) #Psoriatic_Arthritis
#D2M
1️⃣ Failure >= 2 b/tsDMARDs
2️⃣ Problematic
3️⃣ Evidence of persistent dis
+
4️⃣ Exclude drivers like comorbidities & psychosocial factors
🔺️Exclude failure due to Side Effets/CI
#EULAR2025
@RheumNow https://t.co/ULD2Xe6p6A
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Will climate change impact rheumatological care?
#EULAR2025 @rheumnow
Especially larger cities are are affected more.
Need to worry about comorbidities https://t.co/KhTyAssGeI
Links:
Bella Mehta bella_mehta ( View Tweet)
Imagine #Barcelona with an additional 8 degrees in summer 🔥 🔥🔥
Session: Disaster Medicine - Impact of climate change, heat, and global insecurity
#EULAR2025
@RheumNow https://t.co/1TqlBJtoZD
Nelly ZIADE 🍀 Nellziade ( View Tweet)
RA is worst with temperature rising/ climate change.
However SpA has the opposite effect!
Climate change session at #EULAR2025 @RheumNow https://t.co/eKVXnfdEzD
Bella Mehta bella_mehta ( View Tweet)
Tips for Dx RP:
1. Suspect the dx and recognize chondritis.
2. Rule out mimickers
3.Tracheal involvement shows swelling>stenosis (helps ≠from GCA)
4. CV, heme, derm manifestations 🧐VEXAS.
5. biopsy not useful unless ≠ from GCA.
Fantastic session by @Lupusreference https://t.co/W4DgfeRULF
Links:
Adela Castro AdelaCastro222 ( View Tweet)
#EULAR2025 Abstr#POS1155 Fatigue remains a management challenge in #SLE. Consistent with other endpoints achieved, Dapirolizumab+SOC improved fatigue (FACIT-Fatigue & FATIGUE-PRO) over PBO+SOC in a Phase 3 RCT @RheumNow https://t.co/rYujy2YjBl
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What do we do when we see Rx signed of CPPD in RA pts? Do these pts have different trajectory?
Rx Retro study 388 patients RA
18% at least one sign CPPD
ns diff between seeonegative and seropositive pts
RA+CPPD group was
-older
-higher comorbidity score
-more likely to be https://t.co/DaW5DZoDzF
Aurelie Najm AurelieRheumo ( View Tweet)
Vector borne diseases that result in arthritis will rise with climate change/ flooding risk
- Chikungunya
- Dengue
- Zika
- West-Nile Virus
@RheumNow #EULAR2025 https://t.co/HtHyADsOSX
Bella Mehta bella_mehta ( View Tweet)
Climate Change Impacts #Rheumatology Care Taking
HEAT 🥵 causes:
🔺️⬆️ Hospitalisations
🔺️Renal failure ⚠️ NSAIDs
🔺️Flooding: no access to healthcare
🔺️New Infectious diseases mimics RMDs: Zika...
🔺️Insecurities for drug storage and transportation
#EULAR2025
@RheumNow https://t.co/V9RyxYX6Me
Nelly ZIADE 🍀 Nellziade ( View Tweet)
APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA
✅ ACR20: 67–68% vs 47% (PBO)
✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35)
No new safety signals identified.
@RheumNow #EULAR2025 #LB0010 https://t.co/LLN1TXvOC3
Mrinalini Dey DrMiniDey ( View Tweet)
#GameChanger
Subset analysis of #CTD Pts with
Progressive pulmonary fibrosis
#PPF
Ok background #nintedanib 1/3
❎lung IS
2 doses #PDE4Bi #nerandomilast vs #PBO
each dose ⬇️worsening #FVC vs PBO
⬇️lung events - hospital
⬇️death
GI A/E
#EULAR2025 Latebreakers I @RheumNow https://t.co/PWKEnpyyMN
Links:
Janet Pope Janetbirdope ( View Tweet)
Genicular artery embolisation is like so many interventions in MSK medicine:
early promise with smaller RCT & observational data, but the later, more robust data doesn’t show the same benefit.
If you do meta-analyses of all these data, you mix good with bad
#EULAR2025 @RheumNow https://t.co/K1tN9KX8rq
David Liew drdavidliew ( View Tweet)
Management and prognosis of RP by @Lupusreference
1. Pts with mild disease respond to GCs
2. NSAIDs/colchicine good alternatives
3. Most common biologics used: TNFi and IL6i
4. Consider CYP in life threatening dz/ICU pts
5. Dynamic CT assess tracheal collapse.
6. PET-CT can ≠ https://t.co/PNUecMZvkT
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Results from open label
extension of BE-OPTIMAL:
-Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y until 3y.
-No significant major tolerability issues or major SE.
abstract #POS1294
#EULAR2025
@RheumNow https://t.co/VAEiciCR1z
Adela Castro AdelaCastro222 ( View Tweet)
ICI-PMR irAEs are sometimes underestimated compared to inflamm arthritis, but why?
ICI-IA and ICI-PMR look different, but at @HSpecialSurgery, steroid needs and disease impact for both are basically the same. Let’s not devalue either
@lovetolearn27 #EULAR2025 POS1200 @RheumNow https://t.co/NVq2tpjvdu
Links:
David Liew drdavidliew ( View Tweet)
#EULAR2025 Abstr#POS0301 Real World Multicentre study in Italy reported higher proportion of CRR at 6-mth & Lower GC in people with #lupus nephritis (~96% Class III, IV or Mixed with V) treated with Belimumab+SOC vs matched cohort on SOC. Predicted by early BEL use @RheumNow https://t.co/D6e2qo9NRL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA
-ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70
-Also met 2dary endpoints.
-Post hoc https://t.co/S4DhovMCma
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Hidradenitis suppurativa is newer to us in rheumatology, but it seems like inflamm arthritis is a problem - at least to a similar extent as in psoriasis.
Time for us to look for it & to see what therapies like IL-17 inhibitors do for this arthritis
#EULAR2025 POS1237 @RheumNow https://t.co/b5EQdDEAhq
David Liew drdavidliew ( View Tweet)
